





Supplementary Data 1



Gating strategy for identification of Oct4/Sox2 positive cells in patient tissues/cell lines



Supplementary Data 2



## Supplementary Data 3

| <b>Patient</b> | <b>Molecular subtype</b> | <b>Interventions</b>  | <b>Age</b> |
|----------------|--------------------------|---|------------|
| S25            | TNBC                     | NACT with 1 <sup>st</sup> line<br>Doxorubicin/Cyclophosphamide ; peg<br>GCSF support; Docetaxel | 45         |
| S20            | TNBC                     | No chemo  | 37         |
| S21            | ER+PR+HER2-              | No chemo  | 35         |
| S23            | ER+PR+HER2-              | NACT with 1 <sup>st</sup> line<br>Doxorubicin/Cyclophosphamide                                  | 51         |
| S16            | TNBC                     | No chemo  | 54         |
| S28            | ER-PR-HER2+              | NACT 4 cycles; taxane+ 2 cycles<br>Trastuzumab  | 47         |
| S22            | ER+PR+HER2-              | NACT with 1 <sup>st</sup> line<br>Doxorubicin/Cyclophosphamide                                  | 46         |
| S1             | DCIS                     | No chemo  | 63         |
| S18            | ER+PR+HER2+              | NACT with 1 <sup>st</sup> line<br>Doxorubicin/Cyclophosphamide                                  | 44         |

| <b>Site</b> | <b>Forward primer sequence 5'-3'</b> | <b>Reverse primer sequence 5'-3'</b> |
|-------------|--------------------------------------|--------------------------------------|
| 1           | GTGAGCACACGAGGACAAGA                 | GTTGACAACAAACCCGACG                  |
| 2           | ACTTCTGCTGAGCACATCCC                 | CTCCATTCCCACCCAGTCC                  |
| 3           | TGGGTTCAAGGAGGTCAGGA                 | GGGATGTGCTCAGCAGAAGT                 |